Brivlera · DIN 02452952 · 50 mg · tablet
Limited Use, Reason for Use code 548 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 548 required
Write on scriptReason for Use code 548 (criteria below)
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Ontario Limited Use criteria, code 548
Reason for Use code 548
- As adjunctive therapy in the treatment of patients with partial-onset seizures (POS) who have had an inadequate response or have significant intolerance to at least 2 other less costly anticonvulsant therapies (prior or current use); AND
- Patients are not receiving concurrent therapy with levetiracetam; AND
- Patients are under the care of a physician experienced in the treatment of epilepsy.
Note: Less costly anticonvulsant therapies may include the following:
Phenytoin, carbamazepine, gabapentin, lamotrigine, vigabatrin, topiramate, etc.
Coverage limit:
LU Authorization Period: Indefinite
Savings card: RxHelp ONE lists Brivlera (read 2026-09-10) — brand-name savings card, free; cannot be combined with another card on the same claim. (rxhelp.ca ↗)
1 brand, same coverage
Brivlera · DIN 02452952
Manufacturer: UCB Canada Inc.; listing date 2018-12-21
Health Canada: Marketed since 2016-05-02 · brand BRIVLERA · ATC N03AX23 BRIVARACETAM · form Tablet · route Oral · ingredients BRIVARACETAM 50 MG · company Ucb canada inc · schedule Prescription
Ministry pays: $2.1600 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02452952)
Source record
DIN 02452952: Brivlera
Raw flags: sec12=Y, sec3=Y
Item: 281200179; group id 420; item number 1038; lccId 00312; manufacturer id UCB
Source form: Tab; strength: 50mg
Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below
Source prices (unrounded): $4.3200; ministry $2.1600
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02452952
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=93935
Interchangeable products
Apo-Brivaracetam · DIN 02538695 · $2.1600
Auro-Brivaracetam · DIN 02539292 · $2.1600
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02452952
Shortage record checked October 6, 2026